Genetic Architecture of Parkinson’s Disease
-
Published:2023-03
Issue:3
Volume:88
Page:417-433
-
ISSN:0006-2979
-
Container-title:Biochemistry (Moscow)
-
language:en
-
Short-container-title:Biochemistry Moscow
Author:
Shadrina Maria I.,Slominsky Petr A.
Abstract
Abstract
Year 2022 marks 25 years since the first mutation in familial autosomal dominant Parkinson’s disease was identified. Over the years, our understanding of the role of genetic factors in the pathogenesis of familial and idiopathic forms of Parkinson’s disease has expanded significantly – a number of genes for the familial form of the disease have been identified, and DNA markers for an increased risk of developing its sporadic form have been found. But, despite all the success achieved, we are far from an accurate assessment of the contribution of genetic and, even more so, epigenetic factors to the disease development. The review summarizes the information accumulated to date on the genetic architecture of Parkinson’s disease and formulates issues that need to be addressed, which are primarily related to the assessment of epigenetic factors in the disease pathogenesis.
Publisher
Pleiades Publishing Ltd
Subject
Biochemistry,General Medicine,Biochemistry, Genetics and Molecular Biology (miscellaneous),Biophysics,Geriatrics and Gerontology
Reference119 articles.
1. Bandres-Ciga, S., Ahmed, S., Sabir, M. S., Blauwendraat, C., Adarmes-Gomez, A. D., Bernal-Bernal, I., Bonilla-Toribio, M., Buiza-Rueda, D., Carrillo, F., Carrion-Claro, M., Gomez-Garre, P., Jesus, S., Labrador-Espinosa, M. A., Macias, D., Mendez-Del-Barrio, C., Perinan-Tocino, T., Tejera-Parrado, C., Vargas-Gonzalez, L., Diez-Fairen, M., Alvarez, I., Tartari, J. P., Buongiorno, M., Aguilar, M., Gorostidi, A., Bergareche, J. A., Mondragon, E., Vinagre-Aragon, A., Croitoru, I., Ruiz-Martinez, J., Dols-Icardo, O., Kulisevsky, J., Marin-Lahoz, J., Pagonabarraga, J., Pascual-Sedano, B., Ezquerra, M., Camara, A., Compta, Y., Fernandez, M., Fernandez-Santiago, R., Munoz, E., Tolosa, E., Valldeoriola, F., Gonzalez-Aramburu, I., Sanchez Rodriguez, A., Sierra, M., Menendez-Gonzalez, M., Blazquez, M., Garcia, C., Suarez-San Martin, E., Garcia-Ruiz, P., Martinez-Castrillo, J. C., Vela-Desojo, L., Ruz, C., Barrero, F. J., Escamilla-Sevilla, F., Minguez-Castellanos, A., Cerdan, D., Tabernero, C., Gomez Heredia, M. J., Perez Errazquin, F., Romero-Acebal, M., Feliz, C., Lopez-Sendon, J. L., Mata, M., Martinez Torres, I., Kim, J. J., Dalgard, C. L., The American Genome Center, Brooks, J., Saez-Atienzar, S., Gibbs, J. R., Jorda, R., Botia, J. A., Bonet-Ponce, L., Morrison, K. E., Clarke, C., Tan, M., Morris, H., Edsall, C., Hernandez, D., Simon-Sanchez, J., Nalls, M. A., Scholz, S. W., Jimenez-Escrig, A., Duarte, J., Vives, F., Duran, R., Hoenicka, J., Alvarez, V., Infante, J., Marti, M. J., Clarimon, J., Lopez de Munain, A., Pastor, P., Mir, P., Singleton, A., and International Parkinson Disease Genomics Consortium (2019) The genetic architecture of Parkinson’s disease in Spain: characterizing population-specific risk, differential haplotype structures, and providing etiologic insight, Mov. Disord. Offic. J. Mov. Disord. Soc., 34, 1851-1863,
https://doi.org/10.1002/mds.27864. 2. Savitt, J. M., Dawson, V. L., and Dawson, T. M. (2006) Diagnosis and treatment of Parkinson’s disease: molecules to medicine, J. Clin. Invest., 116, 1744-1754,
https://doi.org/10.1172/JCI29178. 3. Vázquez-Vélez, G. E., and Zoghbi, H. Y. (2021) Parkinson’s disease genetics and pathophysiology, Annu. Rev. Neurosci., 44, 87-108,
https://doi.org/10.1146/annurev-neuro-100720-034518. 4. Del Tredici, K., and Braak, H. (2016) Review: sporadic Parkinson’s disease: development and distribution of α-synuclein pathology, Neuropathol. Appl. Neurobiol., 42, 33-50,
https://doi.org/10.1111/nan.12298. 5. Connolly, B. S., and Lang, A. E. (2014) Pharmacological treatment of Parkinson disease: a review, JAMA, 311, 1670-1683,
https://doi.org/10.1001/jama.2014.3654.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|